Catalyst Pharmaceuticals (CPRX) Change in Accured Expenses (2010 - 2026)

Catalyst Pharmaceuticals has reported Change in Accured Expenses for 17 years, with the latest figure at -$9.2 million in Q1 2026.

• For the quarter ending Q1 2026, Change in Accured Expenses fell 260.78% year-over-year to -$9.2 million; the trailing twelve-month figure through Mar 2026 stood at $17.5 million (down 59.11% YoY), and the FY2025 full-year result was $24.2 million, down 55.13% from the prior year.
• Change in Accured Expenses for Q1 2026 stood at -$9.2 million, down from $5.2 million in the prior quarter.
• The five-year high for Change in Accured Expenses was $20.0 million in Q3 2024, with the low at -$9.2 million in Q1 2026.
• Historically, Change in Accured Expenses has averaged $5.4 million across 5 years, with a median of $8.2 million in 2023.
• Annual changes were most pronounced in 2023 — Change in Accured Expenses plunged 316.77% — and 2024, when it jumped 449.88%.
• Catalyst Pharmaceuticals' Change in Accured Expenses stood at $11.5 million in 2022, then declined by 28.82% to $8.2 million in 2023, then rose by 8.67% to $8.9 million in 2024, then slumped by 41.46% to $5.2 million in 2025, then slumped by 276.72% to -$9.2 million in 2026.
• The last three Change in Accured Expenses figures came in at -$9.2 million (Q1 2026), $5.2 million (Q4 2025), and $13.2 million (Q3 2025), per Business Quant data.